Litcius/Paper detail

Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis

Yupeng Guan, Haiyun Xiong, Yupeng Feng, Guolong Liao, Tongyu Tong, Jun Pang

2020Prostate Cancer and Prostatic Diseases98 citationsDOI

Topics & Concepts

MedicineEnzalutamideProstate cancerOncologyInternal medicineDocetaxelAbirateroneLymphocyteCancerNeutrophil to lymphocyte ratioCabazitaxelAndrogen deprivation therapyAndrogen receptorInflammatory Biomarkers in Disease PrognosisProstate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers
Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis | Litcius